<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Monitor Antiobesity Drug Dosing After Rapid Weight Loss

Default sub title

minute read

by Medscape | August 15, 2024
placeholder

A patient who developed atrial fibrillation resulting from the failure to adjust their levothyroxine dose after rapid, significant weight loss while on the antiobesity drug tirzepatide (Zepbound) serves as a key reminder in managing patients experiencing rapid weight loss, either from antiobesity medications or any other means: Patients taking medications with weight-based dosing need to have their doses closely monitored.

Topics: Press Coverage